|
|
|
19.08.26 - 21:24
|
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? (24/7 Wall St.)
|
|
|
Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far. Merck (NYSE:MRK) leads, Amgen (NASDAQ:AMGN) sits second, and Pfizer (NYSE:PFE) trails as a distant third. Merck stock is up 44% year to date (YTD) at $151.67. Meanwhile, Amgen stock is up 35% YTD at $440.84, which isn't bad at all ... Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?...
|
|
|
|
|
18.08.26 - 16:42
|
Crescendo Health Appoints David Strutton, PhD as Chief Scientific Officer (Business Wire)
|
|
|
SAN FRANCISCO--(BUSINESS WIRE)--Crescendo Health, a leader in modernizing clinical research data infrastructure, today announced the appointment of David Strutton, PhD, as Chief Scientific Officer (CSO). In this role, Dr. Strutton will lead the company's scientific strategy, evidence generation frameworks, and customer solutions to advance patient-centric clinical research.
Dr. Strutton brings decades of experience in clinical research, real-world evidence (RWE), and health economics, having led transformative scientific initiatives across the biopharmaceutical and digital health sectors including senior roles at Merck and Pfizer. Dr. Strutton played a pivotal role in establishing Merck's Center for Observational and Real-World Evidence (CORE) and spearheading integrated evidence strategies to support global access to Merck's innovations. At Pfizer, he led Vaccines Global Health and Value, delivering evidence to advance global access to vaccines, through work with national immunization technical adviso...
|
|
|
|
|
17.08.26 - 12:12
|
EMA validates Pfizer and Valneva′s Lyme disease vaccine (PBR)
|
|
|
With this validation, the agency will begin its formal assessment of the application. The submission is supported by efficacy and safety data from the Phase III VALOR clinical
The post EMA validates Pfizer and Valneva's Lyme disease vaccine appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.08.26 - 12:24
|
Valneva Aktie: Borreliose-Impfstoff als großer Wachstumstreiber - Kursziel 12 Dollar (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Valneva-Aktienanalyse von TD Cowen:
Die Analysten von TD Cowen nehmen die Coverage für die Aktie von Valneva SE (ISIN: FR0004056851, WKN: A0MVJZ, Ticker-Symbol: AYJ, Euronext Paris-Symbol: VLA) mit dem Rating "buy" und dem Kursziel von 12 USD auf.
Das Basis-Impfstoffgeschäft des Unternehmens biete Schutz vor Abwärtsrisiken, während LB6V ein "risikoreduzierter" Lyme-Borreliose-Impfstoff sei, der durch eine validierte biologische Grundlage und die regulatorische Expertise von Pfizer gestützt werde, so TD Cowen in einer Research-Note. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
